Literature DB >> 32314845

Eccrine porocarcinoma of the head and neck: Meta-analysis of 120 cases.

Nguyen-Son Le1, Stefan Janik1, David T Liu1, Stefan Grasl1, Muhammad Faisal2,3, Johannes Pammer4, Bettina Schickinger-Fischer5, Jafar-Sasan Hamzavi2, Rudolf Seemann2, Boban M Erovic2.   

Abstract

BACKGROUND: The aim of the study is to analyze potential prognostic factors and to evaluate therapy strategies regarding clinical outcome in patients with eccrine porocarcinoma (EPC) of the head and neck.
METHODS: One hundred and sixteen EPC cases from ninety studies and four authors' EPC cases were included in the meta-analysis.
RESULTS: At an average follow up of 20.48 months, the 3-year overall survival and regional recurrence rate were 70.3% and 19.0%, respectively. Patients without surgical treatment had a significantly worse 3-year overall survival. Mohs microscopic surgery led to significantly less occurrence of regional recurrences compared to wide excision. An ulcerating lesion, high mitotic activity, and lymphovascular invasion were significant prognostic factors.
CONCLUSION: Surgical resection is the cornerstone in the therapy of EPC and represents the therapeutic modality that offers the best chance of disease-free survival. Due to the high probability of recurrence, close follow-ups are strongly recommended.
© 2020 Wiley Periodicals, Inc.

Entities:  

Keywords:  eccrine porocarcinoma; head and neck; malignant eccrine poroma; prognostic factors; treatment outcome

Mesh:

Year:  2020        PMID: 32314845     DOI: 10.1002/hed.26178

Source DB:  PubMed          Journal:  Head Neck        ISSN: 1043-3074            Impact factor:   3.147


  6 in total

1.  Primary Eccrine Porocarcinoma of the Breast: A Case Report and Review of Literature.

Authors:  Yi Xin Li; Mihir Gudi; Zhiyan Yan
Journal:  Case Rep Oncol Med       Date:  2022-05-31

2.  Head and Neck Porocarcinoma: SEER Analysis of Epidemiology and Survival.

Authors:  Matteo Scampa; Rastine Merat; Daniel F Kalbermatten; Carlo M Oranges
Journal:  J Clin Med       Date:  2022-04-14       Impact factor: 4.964

3.  Metastatic Porocarcinoma Effectively Managed by Pembrolizumab.

Authors:  Arminder Singh; Lam Nguyen; Stephanie Everest; Mikhail Vinogradov
Journal:  Cureus       Date:  2021-11-29

4.  Treatment of Malignant Adnexal Tumors of the Skin: A 12-Year Perspective.

Authors:  Marcin Kleibert; Iga Płachta; Anna M Czarnecka; Mateusz J Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Cancers (Basel)       Date:  2022-02-16       Impact factor: 6.639

5.  TROP2 Expression in Sebaceous and Sweat Gland Carcinoma.

Authors:  Takamichi Ito; Hiroki Hashimoto; Yuka Tanaka; Keiko Tanegashima; Maho Murata; Toshio Ichiki; Takeshi Iwasaki; Yoshinao Oda; Yumiko Kaku-Ito
Journal:  J Clin Med       Date:  2022-01-25       Impact factor: 4.241

Review 6.  Current Diagnosis and Treatment Options for Cutaneous Adnexal Neoplasms with Apocrine and Eccrine Differentiation.

Authors:  Iga Płachta; Marcin Kleibert; Anna M Czarnecka; Mateusz Spałek; Anna Szumera-Ciećkiewicz; Piotr Rutkowski
Journal:  Int J Mol Sci       Date:  2021-05-11       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.